at aura biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. by safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. our lead program in ocular melanoma (om), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. the goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. by enabling physicians to treat cancer mo
Company profile
Ticker
AURA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aura Biosciences Securities Corporation • Aura Biosciences B.V. ...
IRS number
320271970
AURA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Departure of Directors or Certain Officers
15 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
EFFECT
Notice of effectiveness
8 Apr 24
S-3
Shelf registration
27 Mar 24
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
27 Mar 24
Latest ownership filings
4
Conor Kilroy
4 Apr 24
3
Conor Kilroy
4 Apr 24
3
Mark Plavsic
25 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
23 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Janet Jill Hopkins
2 Feb 24
4
Julie B Feder
2 Feb 24
4
los Pinos Elisabet de
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 56.37 mm | 56.37 mm | 56.37 mm | 56.37 mm | 56.37 mm | 56.37 mm |
Cash burn (monthly) | (no burn) | 474.00 k | 6.83 mm | 6.49 mm | 5.13 mm | 5.37 mm |
Cash used (since last report) | n/a | 3.27 mm | 47.13 mm | 44.75 mm | 35.43 mm | 37.08 mm |
Cash remaining | n/a | 53.10 mm | 9.24 mm | 11.62 mm | 20.94 mm | 19.29 mm |
Runway (months of cash) | n/a | 112.0 | 1.4 | 1.8 | 4.1 | 3.6 |
Institutional ownership, Q3 2023
75.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 69 |
Opened positions | 6 |
Closed positions | 1 |
Increased positions | 26 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 254.11 bn |
Total shares | 37.29 mm |
Total puts | 1.00 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Matrix Capital Management | 5.36 mm | $48.10 bn |
Medicxi Growth I | 3.04 mm | $52.32 mm |
Medicxi Ventures Management | 3.04 mm | $27.27 bn |
Eventide Asset Managment | 3.02 mm | $27.13 bn |
Adage Capital Partners GP, L.L.C. | 2.88 mm | $25.79 bn |
Citadel Advisors | 2.48 mm | $22.28 bn |
Advent Life Sciences | 2.02 mm | $0.00 |
Lundbeckfond Invest A/S | 2.02 mm | $34.26 mm |
BLK Blackrock | 1.86 mm | $16.72 bn |
Arix Bioscience | 1.51 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Conor Kilroy | Common Stock | Grant | Acquire A | No | No | 0 | 96,000 | 0.00 | 96,000 |
2 Apr 24 | Conor Kilroy | Stock Option Common Stock | Grant | Acquire A | No | No | 7.4 | 144,000 | 1.07 mm | 144,000 |
23 Jan 24 | Julie B Feder | Common Stock | Sell | Dispose S | No | No | 7.6443 | 6,609 | 50.52 k | 62,991 |
23 Jan 24 | los Pinos Elisabet de | Common Stock | Sell | Dispose S | No | No | 7.6415 | 15,853 | 121.14 k | 161,438 |